PL2059260T3 - Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego - Google Patents

Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego

Info

Publication number
PL2059260T3
PL2059260T3 PL07841440T PL07841440T PL2059260T3 PL 2059260 T3 PL2059260 T3 PL 2059260T3 PL 07841440 T PL07841440 T PL 07841440T PL 07841440 T PL07841440 T PL 07841440T PL 2059260 T3 PL2059260 T3 PL 2059260T3
Authority
PL
Poland
Prior art keywords
hgh
pharmaceutical compositions
oral delivery
oral
delivery
Prior art date
Application number
PL07841440T
Other languages
English (en)
Inventor
Moise Azria
Yatindra Joshi
Rosario Lobrutto
Linda Mindeholm
Ashish Bipin Patel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2059260T3 publication Critical patent/PL2059260T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL07841440T 2006-08-31 2007-08-28 Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego PL2059260T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82414006P 2006-08-31 2006-08-31
EP07841440.6A EP2059260B1 (en) 2006-08-31 2007-08-28 Pharmaceutical compositions comprising hGH for oral delivery
PCT/US2007/076932 WO2008027854A2 (en) 2006-08-31 2007-08-28 Pharmaceutical compositions comprising hgh for oral delivery

Publications (1)

Publication Number Publication Date
PL2059260T3 true PL2059260T3 (pl) 2014-03-31

Family

ID=39000473

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07841440T PL2059260T3 (pl) 2006-08-31 2007-08-28 Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego

Country Status (14)

Country Link
US (1) US8323688B2 (pl)
EP (1) EP2059260B1 (pl)
JP (1) JP5042312B2 (pl)
KR (1) KR101524880B1 (pl)
CN (2) CN101557827A (pl)
AU (1) AU2007289344B2 (pl)
BR (1) BRPI0716261A2 (pl)
CA (1) CA2661521C (pl)
ES (1) ES2426485T3 (pl)
MX (1) MX2009002314A (pl)
PL (1) PL2059260T3 (pl)
PT (1) PT2059260E (pl)
RU (1) RU2493868C2 (pl)
WO (1) WO2008027854A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005995A2 (en) 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
WO2008112836A2 (en) * 2007-03-15 2008-09-18 Novartis Ag Pharmaceutical composition comprising human growth hormon
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
MX385591B (es) 2008-08-15 2025-03-18 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
EP2331077A2 (en) * 2008-09-04 2011-06-15 Ironwood Pharmaceuticals, Inc. Stable forlulation comprising therapeutic polypeptides for oral administration
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
JP5805634B2 (ja) * 2009-06-08 2015-11-04 アムニクス オペレーティング インコーポレイテッド 成長ホルモンポリペプチド並びにその作成及び使用方法
WO2011017502A2 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
BR112012018162A2 (pt) 2010-01-22 2017-10-03 Novo Nordisk Healthcare Ag Compostos de hormônio do crescimento estáveis
CN102869677B (zh) 2010-02-17 2015-07-08 硬木药品公司 胃肠病症的治疗
US20130143815A1 (en) 2010-07-22 2013-06-06 Novo Nordisk Health Care Ag Growth hormone conjugates
CA2808091C (en) 2010-08-11 2019-05-21 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
JP6312592B2 (ja) 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化器疾患の治療
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
US12233113B2 (en) 2016-02-17 2025-02-25 Genexine, Inc. Pharmaceutical composition comprising recombinant hGH for the treatment of growth hormone deficiency
JOP20190019A1 (ar) 2016-08-30 2019-02-12 Genexine Inc تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
CR20230308A (es) * 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1996040072A2 (en) * 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4975201B2 (ja) 1997-02-07 2012-07-11 エミスフェアー・テクノロジーズ・インク 化合物及び活性剤を送達するための組成物
NZ501961A (en) * 1997-07-04 2001-11-30 Pharmacia & Upjohn Ab A therapy for improving cellular function in a heart challenged by insulin resistance, thereby protecting the heart from complications arising from this condition
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
WO2003015822A1 (en) * 2001-08-17 2003-02-27 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
DK1581251T3 (da) * 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf
MXPA05011832A (es) * 2003-05-09 2006-02-17 Neose Technologies Inc Composiciones y metodos para la preparacion de mutantes de glicosilacion de la hormona de crecimiento humano.
PT1651248E (pt) 2003-07-11 2009-11-10 Novartis Ag Composições farmacêuticas para dose oral compreendendo um agente de administração na forma micronizada
PL1651249T3 (pl) 2003-07-23 2013-04-30 Novartis Ag Zastosowanie kalcytoniny w zapaleniu kości i stawów
CA2538846A1 (en) * 2003-09-19 2005-03-31 Pfizer Health Ab Enhanced method of treatment of growth disorders
WO2007005995A2 (en) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
AU2006292337B8 (en) 2005-09-19 2013-02-07 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid

Also Published As

Publication number Publication date
ES2426485T3 (es) 2013-10-23
JP2010502639A (ja) 2010-01-28
CA2661521C (en) 2016-04-12
EP2059260A2 (en) 2009-05-20
CN103356997A (zh) 2013-10-23
MX2009002314A (es) 2009-03-20
WO2008027854A3 (en) 2008-07-03
KR101524880B1 (ko) 2015-06-01
US8323688B2 (en) 2012-12-04
AU2007289344B2 (en) 2011-04-14
BRPI0716261A2 (pt) 2013-08-06
CA2661521A1 (en) 2008-03-06
CN101557827A (zh) 2009-10-14
JP5042312B2 (ja) 2012-10-03
EP2059260B1 (en) 2013-06-19
RU2493868C2 (ru) 2013-09-27
KR20090045416A (ko) 2009-05-07
AU2007289344A1 (en) 2008-03-06
US20100247608A1 (en) 2010-09-30
PT2059260E (pt) 2013-09-03
WO2008027854A2 (en) 2008-03-06
RU2009111391A (ru) 2010-10-10

Similar Documents

Publication Publication Date Title
PL2059260T3 (pl) Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego
ZA200710734B (en) Compositions for drug delivery
PT2152195E (pt) Produto farmacêutico peptídico para distribuição oral
EP1968554A4 (en) BIOADHESIVE MEDICATION FORMULATIONS FOR ORAL TRANSMUCOSAL ADMINISTRATION
SI3984528T1 (sl) Farmacevtski sestavki, ki vsebujejo nilotinib
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
GB0713625D0 (en) Pharmaceutical compositions
SI2124556T1 (sl) Farmacevtske sestave
IL220800A (en) Stabilized Pharmaceutical Preparations Containing Passoterodine
IL248492A0 (en) Pharmaceutical preparations for administration into the ventricles of the brain
EP2143424A4 (en) ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
EP2010162A4 (en) COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
EP2226071A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
GB0608724D0 (en) Novel Pharmaceutical Compositions
IL208325A0 (en) Stabilizing lipis compositions for oral pharmaceutical agents
GB0610322D0 (en) Novel pharmaceutical compositions
EP1809291A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL LEVY
EP2109454A4 (en) PHARMACEUTICAL COMPOSITIONS BASED ON GLP-1
IL198160A0 (en) Pharmaceutical formulations
ZA201102405B (en) Pharmaceutical composition for oral administration
EP2197454A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
ZA200904725B (en) GLP-1 Pharmaceutical compositions
ZA200808030B (en) Pharmaceutical compositions